Coronavirus (COVID-19) Update: FDA provides guidance on production of alcohol-based hand sanitizer to help boost supply, protect public health


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Coronavirus (COVID-19) Update FDA provides guidance on production of alcohol based hand sanitizer to help boost supply protect public health
The agency realizes that manufacturers and compounders will need time to ramp up production as they obtain the ingredients needed to make these hand sanitizers. During this time the FDA will work to assist them as they develop hand sanitizers to make available for the American public.

As part of the U.S. Food and Drug Administration's ongoing commitment to address the coronavirus (COVID-19) pandemic, the agency has issued two guidance documents to communicate its policy for the temporary manufacture of certain alcohol-based hand sanitizer products. These guidance documents will be in effect for the duration of the public health emergency declared by the Secretary of Health and Human Services (HHS) on January 31, 2020.

"We are aware of significant supply disruptions for alcohol-based hand sanitizers. Many manufacturers make hand sanitizers, and several have indicated that they are working to increase supply," said FDA Commissioner Stephen M. Hahn, M.D. "In the meantime, these guidances provide flexibility to help meet demand during this outbreak. We will continue to work with manufacturers, compounders, state boards of pharmacy and the public to increase the supply of alcohol-based hand sanitizer available to Americans."

Because of an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, there have been reports of some consumers attempting to make hand sanitizers for personal use. The agency lacks information on the methods being used to prepare such products and whether they are safe for use on human skin.

The guidance, Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19), is immediately in effect and outlines that the agency does not intend to take action against manufacturing firms that prepare alcohol-based hand sanitizers for consumer use and for use as health care personnel hand rubs during this ongoing public health emergency as described in the guidance.

The second guidance, Policy for Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency, is in effect for the temporary compounding of certain alcohol-based hand sanitizers by pharmacists in state-licensed pharmacies or federal facilities and registered outsourcing facilities. Compounding is generally a practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes, or alters ingredients of a drug to create a tailor-made medication. The temporary policy outlined by the agency does not require compounders to obtain a patient-specific prescription.

The FDA's guidance documents apply only to handrub products prepared using the United States Pharmacopoeia or Food Chemical Codex grade ingredients specifically described in the guidance, consistent with World Health Organization recommendations. The guidance documents also discuss product labeling and certain manufacturing methods and reporting requirements, such as that manufacturers must have a way to accept and submit adverse event reports to FDA for any products they manufacture.

The agency realizes that manufacturers and compounders will need time to ramp up production as they obtain the ingredients needed to make these hand sanitizers. During this time the FDA will work to assist them as they develop hand sanitizers to make available for the American public.

Tags : #Fda #Handsanitizer #Guidelines

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Healthcare Trends in 2026: What India's Doctors, Hospitals, and Patients Need to KnowJuly 18, 2026
Monsoon Health Problems in India: Understanding the Risks, Symptoms, and PreventionJuly 18, 2026
Fortis Escorts Faridabad Launches Faridabad’s First Comprehensive Lung Failure Clinic for Advanced Respiratory and Transplant CareJuly 17, 2026
What Seemed Like Persistent Gas Turned Out To Be A 30-cm Rare Cancer Occupying Most Of Her AbdomenJuly 17, 2026
Kidney Stone Prevention Initiative Unites More Than 8,200 Doctors Across India, Earns Asia Book of Records RecognitionJuly 17, 2026
Moscow radiologists introduce AI tool for hip dysplasia diagnosisJuly 17, 2026
Sharrp Ventures leads 100 CR investment in Naturis Cosmetics’ first institutional funding roundJuly 17, 2026
Eugenix Challenges Hair Loss Stigma With Nationwide 'I Chose Transformation' Campaign Featuring Boney KapoorJuly 17, 2026
How Artificial Intelligence is Reshaping Preventive Healthcare Through Earlier Detection and Smarter Clinical InsightsJuly 17, 2026
Five Common Myths About Children's Urinary Problems That Parents Should Stop BelievingJuly 17, 2026
Robotics in Surgery: How Robot-Assisted Procedures Are Transforming Healthcare in IndiaJuly 17, 2026
Wearable Health Devices: How Smart Technology Is Changing Healthcare in IndiaJuly 17, 2026
Sankara Eye Hospitals Successfully Hosts 20th Annual VISION 2020 India Conference, Celebrating 50 Years of the Sankara MovementJuly 16, 2026
Manipal Hospital Bhubaneswar Successfully Treats Rare Brain Injury Caused by Post-Traumatic Workplace AccidentJuly 16, 2026
Immuneel Therapeutics and Tata Memorial Centre Sign Strategic MoU to Advance Cell and Gene Therapy Research in India July 16, 2026
Breast Cancer Early Warning Signs: What Every Woman in India Needs to KnowJuly 16, 2026
HbA1c Test Explained: What It Measures, Normal Range, and Why It Matters for IndiansJuly 16, 2026
Not Just Weight Loss: How Bariatric Surgery Improves Diabetes, PCOS, and Thyroid-Related Health ChallengesJuly 15, 2026
Leiutis Pharmaceuticals announces CDSCO approval for Global-First Synthetic CBD Therapy for Mild to Moderate Anxiety DisordersJuly 15, 2026
Dr Agarwals Institute of Optometry and SASTRA University Jointly Launch Optometry ProgrammeJuly 15, 2026